Literature DB >> 2458065

Treatment of patients with neuropathy and anti-MAG IgM M-proteins.

E Nobile-Orazio1, L Baldini, S Barbieri, P Marmiroli, G Spagnol, E Francomano, G Scarlato.   

Abstract

Five patients with neuropathy and IgM M-proteins that reacted with myelin-associated glycoprotein (MAG) were treated for 10 to 20 months with cytostatic agents. In 2 patients, a decrease in serum M-protein and in anti-MAG IgM levels coincided with a progressive improvement of neuropathy. No clinical improvement and no decrease of anti-MAG IgM were observed in the other patients. The close relationship between the decrease of anti-MAG M-proteins and clinical improvement in these patients supports the pathogenetic role of the M-protein in the neuropathy.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2458065     DOI： 10.1002/ana.410240118

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  22 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.

Authors:  X Mariette; C Chastang; P Clavelou; J P Louboutin; J M Leger; J C Brouet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

4.  Proximal motor neuropathy, IgA paraproteinaemia and anti-myelin-associated glycoprotein reactivity.

Authors:  T Hemachudha; P Phanuphak; K Phanthumchinda; S Kasempimolporn
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

Review 5.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

Review 6.  Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.

Authors:  J M Leger; A B Younes-Chennoufi; B Chassande; G Davila; P Bouche; N Baumann; P Brunet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

7.  Measuring ataxia: quantification based on the standard neurological examination.

Authors:  N C Notermans; G W van Dijk; Y van der Graaf; J van Gijn; J H Wokke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

8.  Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.

Authors:  J H Ernerudh; M Vrethem; O Andersen; C Lindberg; G Berlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  Autoantibodies to cerebroside sulphate (sulphatide) in leprosy.

Authors:  P R Wheeler; J G Raynes; K P McAdam
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

10.  IgG monoclonal paraproteinaemia and peripheral neuropathy.

Authors:  A F Bleasel; S H Hawke; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.